GW 501516, commonly called Cardarine, is an experimental compound that activates a specific receptor in your cells to shift your body’s energy source from glucose toward fat. It was originally developed in the 1990s by GlaxoSmithKline as a potential treatment for metabolic and cardiovascular disease, but clinical development was abandoned before it ever reached approval. Despite never being approved for human use, it circulates widely in the performance-enhancement underground, primarily for its effects on endurance and fat metabolism.
How It Works Inside Your Cells
GW 501516 is not a steroid or a hormone. It belongs to a class of compounds called PPARδ agonists, meaning it activates a specific type of receptor found in the nucleus of your cells. These receptors, called peroxisome proliferator-activated receptors, act as transcription factors: once a molecule like GW 501516 binds to them, they pair up with another receptor and latch onto specific stretches of DNA, switching target genes on or off. GW 501516 was the first highly selective synthetic compound designed to activate the delta subtype of this receptor family.
The practical result of flipping those genetic switches is that your cells ramp up the machinery for burning fatty acids. A key enzyme in the fat-oxidation pathway gets upregulated, while pathways that break down glucose for energy get dialed down. In animal studies, this shows up as a measurably lower respiratory exchange ratio, a standard indicator that the body is pulling a greater share of its fuel from fat rather than carbohydrates.
Effects on Endurance and Muscle Fuel
The effect that made Cardarine famous in athletic circles is its impact on endurance. In mouse studies, animals treated with GW 501516 ran significantly longer before exhaustion. The mechanism is straightforward: by forcing muscles to preferentially burn fat, the compound preserves glycogen stores, the limited sugar reserves that muscles typically deplete during sustained effort. When glycogen runs out, performance collapses. Delay that depletion, and you extend the clock.
Metabolomic analysis of treated mice showed that glycolysis (the breakdown of sugar in muscle tissue) was substantially reduced, especially in the period immediately after exhaustive running. At the same time, markers of fat metabolism were elevated. Interestingly, exercise alone also increases fat oxidation in muscle, but training simultaneously ramps up protein breakdown as an energy source. GW 501516 appears more targeted: it predominantly drives fat metabolism without the same increase in protein breakdown, at least in animal models.
The compound also appeared to suppress gluconeogenesis, the process by which the body converts amino acids into glucose when sugar runs low. In treated mice, the amino acid spikes normally seen after hard exercise were blunted, suggesting the animals relied almost exclusively on fatty acids for fuel.
Effects on Cholesterol and Blood Lipids
GW 501516 did reach early-stage human trials before its development was halted, and the lipid data from those trials is notable. In subjects with low HDL (“good”) cholesterol and features of metabolic syndrome, the compound at a 10 mg dose raised HDL cholesterol by up to 16.9% and increased a key structural protein of HDL particles by 6.6%. On the other side of the ledger, LDL (“bad”) cholesterol dropped 7.3%, triglycerides fell 16.9%, and free fatty acids decreased 19.4%.
The changes went deeper than headline cholesterol numbers. An exploratory analysis found that very-low-density lipoprotein particles dropped 19%, intermediate-density lipoproteins fell 52%, and LDL particles decreased 14%, with the reduction concentrated in the small, dense LDL particles most strongly linked to cardiovascular risk. HDL particle count rose 10%, with gains in the medium and large particles considered most protective. Overall, the shift pointed toward a significantly less harmful lipoprotein profile. These were real, measurable changes in humans, which is part of why the compound attracted so much interest before safety concerns ended its clinical development.
What It Does Not Do
Despite early speculation, GW 501516 does not appear to directly improve insulin sensitivity or glucose uptake in skeletal muscle. Research in muscle cell lines showed that while the compound successfully increased fat oxidation and turned on genes associated with mitochondrial activity, it failed to enhance insulin signaling, boost glucose uptake, or activate the cellular energy sensor AMPK. Any improvements in whole-body glucose handling seen in animal studies likely stem from the downstream effects of burning more fat and carrying less of it in the bloodstream, rather than a direct action on the insulin pathway in muscle.
It is also not anabolic. GW 501516 does not build muscle tissue the way testosterone or other anabolic agents do. Its effects are metabolic, not structural.
Why Development Was Abandoned
GlaxoSmithKline halted clinical development of GW 501516 after preclinical toxicology studies in rodents revealed rapid cancer development in multiple organ sites. The cancers appeared at doses and durations that, while higher than what humans would typically use, raised serious enough red flags that the company chose not to continue. No long-term human safety data exists because the trials never progressed that far. The absence of human safety data is itself a risk factor: there is simply no way to know what prolonged use does in people.
This is the central tension of the compound. Its metabolic effects are genuinely striking, particularly the lipid changes seen in human trials. But the animal cancer signal was strong enough to kill a drug with blockbuster commercial potential, which gives you a sense of how seriously the manufacturer took the findings.
Regulatory and Legal Status
The World Anti-Doping Agency prohibits GW 501516 at all times, both in and out of competition. It falls under category S4.4, metabolic modulators, alongside other PPARδ agonists. It is classified as a non-specified substance, which is the more serious designation under WADA rules, meaning athletes who test positive face harsher default sanctions than they would for many other banned substances. Multiple athletes across cycling, track and field, and other endurance sports have received bans after testing positive.
GW 501516 is not approved by the FDA or any other national drug regulatory agency for any medical use. It is not legally sold as a pharmaceutical. Products containing it are typically marketed as “research chemicals” to skirt regulations, and quality control on these products is essentially nonexistent. Independent testing of black-market compounds routinely finds inaccurate dosing, contamination, or substituted ingredients.
The Bottom Line on What It Does
GW 501516 reprograms your cells’ fuel preference, pushing them to burn fat instead of sugar. In animals, this translates to dramatically improved endurance. In humans, it produces favorable shifts in cholesterol and blood lipid profiles. It does not build muscle, and its effects on blood sugar appear to be indirect. The compound was never approved for human use, and its development was stopped over cancer findings in animals. It remains banned in all competitive sports as a metabolic modulator.